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Although bipolar disorder (BP) is one of the most heritable psychiatric conditions,
susceptibility genes for the disorder have yet to be conclusively identiﬁed. It is likely that
variants in multiple genes across multiple pathways contribute to the genotype–phenotype
relationship in the affected population. Recent evidence from genome-wide association
studies implicates an entire class of genes related to the structure and regulation of ion
channels, suggesting that the etiology of BPmay arise from channelopathies. In this review,
we examine the evidence for this hypothesis, with a focus on the potential role of voltage-
gated potassium channels. We consider evidence from genetic and expression studies,
and discuss the potential underlying biology. We consider animal models and treatment
implications of the involvement of potassium ion channelopathy in BP. Finally, we explore
intriguing parallels between BP and epilepsy, the signature channelopathy of the central
nervous system.
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GENETIC EPIDEMIOLOGY
Bipolar disorder (BP) is a disabling psychiatric condition with a
considerable public health impact, affecting 1–2% of the general
population (Weissman et al., 1996). Family, twin, and adoption
studies show that genetic factors play a leading role in is etiology.
Family studies suggest that compared to the general population
the risk of BP is 5–10 times greater in siblings of a proband with
the disorder (Craddock and Jones, 1999) and twin studies provide
estimates of heritability for BP that range from 80 to 90%, rank-
ing it among the most heritable of psychiatric disorders (Barnett
and Smoller, 2009). However, conclusive ﬁndings from molecular
studies to identify relevant genetic factors have proven elusive, and
the genetic architecture remains unresolved. Although results from
sequencing analyses may reveal rare variants with large effects on
the level of the individual, single variants are not likely to inﬂu-
ence BP risk at the population level (Craddock and Sklar, 2009).
Rather, multiple genetic phenomena likely contribute to BP risk,
including the additive and interactive effects ofmany variants, each
contributing a small effect, as well as heterogeneity across popu-
lations. This has lead to an interest in identifying the molecular
pathways that are disrupted by these risk variants, any number of
which may underlie an individual’s susceptibility to BP (Askland
et al., 2009).
GENOME-WIDE ASSOCIATION STUDIES
Encouraged by the evidence from genetic epidemiology studies,
considerable effort has been expended over the past two decades to
identify susceptibility genes for BP. The completion of the Human
Genome Project and advances in high-throughput genotyping
technology spurred a new generation of genome-wide association
studies (GWAS) making it possible to test for genetic associa-
tions at sites of common polymorphic variation in an unbiased
manner across the entire genome. The ﬁrst GWAS of BP with
individual level genotype data came from the Wellcome Trust
Case Control Consortium (WTCCC; Wellcome Trust Case Con-
trol Consortium, 2007). The WTCCC simultaneously conducted
a GWAS of seven different disorders, including BP. Two thou-
sand cases for each disorder and a common set of 3,000 controls
were genotyped at <500,000 single-nucleotide polymorphisms
(SNPs) across the genome. The analysis of data on BP revealed
no ﬁndings that were considered genome-wide signiﬁcant. Soon
afterward, another GWAS of BP was reported from the Systematic
Treatment Enhancement Program for Bipolar Disorder (STEP-
BD; Sklar et al., 2008). In this study, a total of 1,461 cases with
BP from the STEP-BD trial and the University College of London
(UCL) and 2,008 controls were genotyped. As with the WTCCC,
none of the ﬁndings were genome-wide signiﬁcant. Given the her-
itability of BP, the lack of genome-wide signiﬁcant ﬁndings and
generally inconsistent results from these early GWAS highlighted
the fact that the common variants are likely to represent genetic
effects of modest size.
It was not until large samples from several different studies
were combined in a mega-analysis that compelling ﬁndings for
BP began to emerge. In 2008, Ferreira et al. (2008) reported a
GWAS of 4,387 BP cases and 6,209 controls from the WTCCC,
STEP-UCL, and ED-DUB-STEP2 datasets with over 1.8 million
genotyped and imputed SNPs. This was the largest GWAS to
date and it reported the ﬁrst genome-wide signiﬁcant associa-
tion in BP [rs10994336, odds ratio (OR) = 1.45, p = 9.1 × 10−9]
at ANK3 (ankyrin G). Schulze et al. (2009) subsequently repli-
cated the ﬁndings with ANK3 in a candidate gene study using
a sample that had previously been part of a pooled GWAS
(Baum et al., 2008). They found signiﬁcant associations with
two SNPs in ANK3, including the SNP reported by Ferreira
et al. (2008; rs9804190, OR = 1.32, p = 3 × 10−6; rs10994336,
OR = 1.54, p = 1.7 × 10−5). The two SNPs were ∼340 kb
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apart with little linkage disequilibrium between them, suggest-
ing the possibility of independent loci contributing to allelic
heterogeneity.
Three GWAS (Scott et al., 2009; Smith et al., 2009; Lee et al.,
2010) were subsequently reported, including one (Smith et al.,
2009) of 1,001 BP cases and 1,033 controls of European-American
ancestry and 345 BP cases and 670 controls of African-American
ancestry from the National Institute of Mental Health (NIMH)
Genetic Association Information Network (GAIN), a second
(Scott et al., 2009) on 2,076 BP cases and 1,676 controls of
European-American ancestry that partially overlapped with the
ﬁrst, and a third (Lee et al., 2010) on 1,000 BP cases and 1,000
controls of Han Chinese ancestry. None of the ﬁndings from
these three GWAS met criteria for genome-wide signiﬁcance, but
provided further conﬁrmatory evidence for an association with
ANK3. Scott et al. (2009) carried out a ﬁxed effects meta-analysis
of rs10994336with thepreviously publishedﬁndings andprovided
the strongest evidence yet of association with ANK3 (OR = 1.47,
p = 1.1 × 10−10).
To improve the power to detect susceptibility variants in BP and
other complex psychiatric disorders, a landmark initiative referred
to as the Psychiatric GWAS Consortium (PGC) was undertaken
to assemble existing samples of BP, schizophrenia, depression,
attention-deﬁcit hyperactivity disorder (ADHD), and autism and
carry out the largest GWAS ever conducted with these disorders
(Psychiatric GWAS Consortium Coordinating Committee et al.,
2009). The mega-analysis led by the PGC-BP (Psychiatric GWAS
Consortium Bipolar Disorder Working Group, 2011) brought
together an international sample of 7,481 BP cases and 9,250 con-
trols with imputed genotype data on ∼2.5 million SNPs. The top
ﬁnding was again in ANK3 with an OR = 1.35 (p = 7.1 × 10−9)
at rs10994397, which is approximately 99 kb from rs10994336, the
SNP that was highlighted in the original Ferreira et al.’s (2008)
study. When combined with an independent replication sample
of 4,496 BP cases and 42,422 controls, the most signiﬁcant ﬁnd-
ing to emerge was at rs4765913 in CACNA1C with an OR = 1.14
(p = 1.52 × 10−8).
The convergence of ﬁndings around ANK3 and CACNA1C
has suggested a biologically plausible etiologic mechanism in BP.
ANK3 is an adaptor protein that regulates the distribution of
voltage-gated ion channels, and CACNA1C is the alpha 1C sub-
unit of the L-type voltage-gated calcium channel. This lent further
support to the burgeoning hypothesis that BPmay be an ion chan-
nelopathy (el-Mallakh and Wyatt, 1995; El-Mallakh and Huff,
2001; Askland, 2006; Askland and Parsons, 2006; Casamassima
et al., 2010). Pathway-based analyses of GWAS data, which col-
lectively tests for associations of SNPs across sets of genes within
deﬁned molecular pathways instead of testing each SNP indepen-
dently (Askland et al., 2009), has provided further evidence for this
hypothesis.
A recent pathway-based analysis (Askland et al., 2009) was car-
ried out with data from the NIMH GAIN and WTCCC GWAS
using gene sets based on gene ontology (GO) categories. Results
from this analysis implicated genes involved in the structure and
regulation of ion channels. Of the 16 gene sets that were sta-
tistically signiﬁcant (p < 0.01) in the NIMH GAIN discovery
sample, nine were ion channel/binding/transporter sets. Eight of
these nine were replicated in the WTCCC sample. Notably, the
most signiﬁcant group in the NIMH GAIN sample, which was
also replicated in the WTCCC sample, was a gene set involved in
voltage-gated ion channel activity. Since only four genes overlap in
the gene sets between samples, it appears that the sharedmolecular
function (mediation of voltage-gated ion channel activity) rather
than a few highly signiﬁcant results common across studies drove
the results.
Another pathway-based analysis (Le-Niculescu et al., 2009)
used a convergent functional genomics (CFG) approach to iden-
tify gene sets of interest. They ﬁrst extracted nominally signiﬁcant
signals (p < 0.05) from three GWAS studies (WTCCC, German,
and NIMH GAIN datasets; Fangerau et al., 2004; Wellcome Trust
Case Control Consortium, 2007; Baum et al., 2008), and pri-
oritized potential candidates based on independent, converging
lines of evidence from various bioinformatics resources. Results
implicated gene sets involved in calcium and potassium reg-
ulation, as well as cellular adhesion, thus providing further
evidence implicating dysregulation of ion channel machinery
in BP.
In the largest GWAS of psychiatric illness to date, a recent
analysis from the PGC Cross-Disorder Group (Cross-Disorder
Group of the Psychiatric Genomics Consortium et al., 2013)
combined various approaches to examine a potentially shared
genetic contribution to ﬁve psychiatric disorders: major depres-
sive disorder, bipolar disorder, schizophrenia, autism spectrum
disorders, and ADHD (total N = 33,332 cases and 27,888 con-
trols). Methods included multinomial logistic regression with
model selection, polygenic risk score analysis, pathways analysis,
and an enrichment analysis of expression quantitative trait loci
(eQTL) data. In the primary analysis, two of the four genome-
wide signiﬁcant results were in calcium channel genes (CACNA1C
and CACNB2), and model selection supported a contribution of
these variants to multiple disorders. Additionally, results from
the pathways analysis suggested that genes involved in calcium
channel activity have pleiotropic effects amongmultiple disorders.
These ﬁndings suggest that variants which alter calcium channel
functioning contribute not only to BP, but also to a shared, fun-
damental mechanism that contributes to a broader deﬁnition of
psychopathology.
GENETIC FINDINGS WITH POTASSIUM ION CHANNELS
Because of the ﬁndings with CACNA1C, most of the attention
has understandably focused on the role of calcium ion chan-
nels in BP. However, the possibility that potassium ion channels
may also contribute to the etiology of BP was suggested by a re-
analysis of GWAS data from the NIMH GAIN sample (reported
in a companion paper in this issue). Given that ANK3 encodes
a protein known to molecularly interact with other membrane
bound proteins in neurons, we sought to test whether interac-
tions betweenANK3 and genes encoding these other proteins may
contribute to BP susceptibility. Using the STRING 9.0 bioinfor-
matics database (Szklarczyk et al., 2011), which collates existing
evidence of protein–protein interactions, we identiﬁed putative
interactors with ANK3. We then tested for interactions between
SNPs in ANK3 and in these interacting proteins in association
with BP. The most signiﬁcant ﬁndings were between ANK3 and
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KCNQ2 (p = 3.18 × 10−8), which remained signiﬁcant after
accounting for multiple testing. These interactions were driven by
two SNPs in KCNQ2, rs2282150 (an intronic SNP) and rs2297385
(a synonymous coding SNP), interacting with 16 different SNPs
in ANK3 that all fall within the boundaries of ankyrin repeats,
which are functional domains known to mediate protein–protein
interactions. We were able to replicate these associations using
data from theWTCCC sample. We also found suggestive evidence
of interactions between ANK3 and KCNQ3 (p = 1.86 × 10−5).
KCNQ2 and KCNQ3 encode proteins that form hetero-tetramer
complexesmaking up the voltage-gated potassium ion channels in
neurons.
Interestingly, previous genetic studies have implicated potas-
sium related genes in BP. For example, of the over 40 linkage
regions that had been reported in genome-wide linkage studies of
BP (Newton, 2007), one of the most prominent implicated chro-
mosome 8q24, a region that includes KCNQ3. The 8q24 region
initially reached a logarithm (base 10) of odds (LOD) score of
2.39 in a genome-wide scan by the Johns Hopkins Mood Dis-
orders Research Group (Friddle et al., 2000). This ﬁnding was
strengthened by including additional pedigrees (McInnis et al.,
2003) and markers [Avramopoulos et al., 2004; non-parametric
linkage (NPL) = 3.13 and 3.25, respectively]. It was also repli-
cated in an independent sample by a German group (Cichon
et al., 2001; LOD = 3.6). A meta-analysis using primary genotype
data from 11 genome-wide linkage scans again indicated 8q as
one of only two signiﬁcant regions in the genome (LOD = 3.4;
McQueen et al., 2005). Zandi et al. (2007) ﬁne mapped a 3.4-
Mb region under the linkage peak with 249 informative SNPs.
This family-based association analysis with 155 nuclear families
identiﬁed a nominally signiﬁcant SNP (rs1901090, p < 0.05)
and haplotype (rs2945733–rs1901090, p = 0.003) near the gene.
Finally, this region was further probed with 2,756 observed and
15,552 imputed genotypes (Zhang et al., 2010), the most signiﬁ-
cant of which (rs2673582, p = 4.80× 10−5) lies 27 kb upstream of
KCNQ3.
KCNQ2 has also been implicated in BP by candidate gene
association studies. One study (Borsotto et al., 2007) found two
signiﬁcant associations with SNPs in KCNQ2 (p < 0.05). The
results from this study are particularly interesting given the func-
tional consequences of these variants within KCNQ2, which
suppressed the potassium channel activity. The authors hypothe-
sized that this might result in hyperexcitable neurons, which are
characteristic of manic and hypomanic states.
Other candidate gene studies of BP have implicated KCNN3, a
voltage-independent calcium-activated potassium channel, which
is thought tomediate neuronal excitability via the slow component
of synaptic afterhyperpolarization that follows an action poten-
tial event. The highly polymorphic CAG-repeat array in exon 1
had been implicated in BP (Chandy et al., 1998; Wittekindt et al.,
1998; Hawi et al., 1999; McInnis et al., 1999; Rohrmeier et al.,
1999). However, a meta-analysis of pooled evidence from these
individual studies was null (Glatt et al., 2003). The authors of
the meta-analysis noted that the polymorphism in question, or
one in LD with it, might yet be associated with a subpheno-
type of the disorder, such as anticipation or symptom severity.
Indeed, a more recent analysis of a schizophrenic sample found an
association between the longCAG repeats (which reduce the chan-
nel’s functioning) and better cognitive performance on tasks that
measured the ability to discriminate, select, and execute (Grube
et al., 2011).
A series of gene expression studies have provided further evi-
dence for a role of potassium ion channels in BP. Using post
mortem striatum samples of human brains from the Stanley
Foundation Brain Collection [including the nucleus accumbens
(Str-NAc) and the lateral cerebellar hemisphere], one group
(Smolin et al., 2012) analyzed expression of 72 different ion chan-
nel subunits. They found altered gene expression patterns in BP,
with a signiﬁcant up-regulation of KCNQ2 (fold change: 1.51,
p = 0.039677),KCNQ3 (fold change: 7.00, p = 0.005305),KCNA4
(fold change: 2.03, p = 0.002), as well as signiﬁcant up-regulation
of two α- and β-subunits of voltage-gated type I sodium channel
genes (SCN1A and SCN1B) in the lateral cerebellar hemisphere. In
the Str-NAc, they found a signiﬁcant down-regulation of KCNS3
(fold change: −1.67, p = 0.00082), KCNA1 (fold change: −1.59,
p = 0.00396), and up-regulation of KCNN3 (fold change: 1.57,
p = 0.04719). Due to the known ability of mood-stabilizing drugs
to directly interfere with ion channel activity, they also looked
for differential expression among the 72 genes between subjects
on versus off mood stabilizers. Interestingly, the only signiﬁcant
genes were KCNQ3 (p = 0.012) and SCN1B (p = 0.004) in the
cerebellum.
In a gene expression study using an animal model, whole-
brain mRNA from mice treated with antipsychotics (clozapine,
haloperidol, or olanzapine) was examined (Duncan et al., 2008).
The results of the study suggested that treatment with antipsy-
chotics altered regulation of two genes encoding subunits of the
Kv1 potassium voltage-gated channel, shaker related subfam-
ily: KCNA1 and KCNAB1, as well as the Kv channel-interacting
protein KCHIP. The authors of the study concluded that the
modulation of neuronal voltage-gated ion channels, particularly
potassium and sodium, contribute to the mechanism of action for
antipsychotics via their effects on neuronal electrical activity and
neurotransmission.
In two other gene expression studies with animal models,
the effect of electroconvulsive therapy (ECT) on the expression
levels of voltage-gated potassium channel subunits in rat brain
was examined (Pei et al., 1997; Hjaeresen et al., 2008). ECT is a
pro-convulsive treatment in which electrical currents are passed
through the brain in order to induce a brief seizure (Mayo Clinic,
2010). However, over time, ECT actually has anticonvulsive prop-
erties (Sackeim, 1999). Its primary indication is for the treatment
of major depression, although there is anecdotal evidence for its
use in treating mania (Versiani et al., 2010). The ﬁrst study found
that the expression levels of the potassium channel genes were
affected by both chronic and acute ECT, and that these effects
were speciﬁc to channel type, brain region, and timing (Pei et al.,
1997). The second study also found that chronic ECT signiﬁcantly
(p< 0.001) increased expression levels, again in a channel subtype
and brain region speciﬁc manner (Hjaeresen et al., 2008). Since
potassium channel genes are integral to the regulation of mem-
brane potentials, the authors concluded that the increased levels of
mRNA might be at least partially relevant to the seizure threshold
elevating effect of ECT.
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ION CHANNELS AS THERAPEUTIC TARGETS
Ion channels provide an attractive target for pharmacological
intervention, given their diverse and ubiquitous roles in a broad
range of physiological processes. Among all drugs with known tar-
gets, approximately 13.4% have their primary therapeutic action
at ion channels. This ranks ion channels second as a target class,
behind G protein-coupled receptors (GPCRs; Overington et al.,
2006).
Accumulating evidence suggests that existing treatments for BP
may potentially exert their therapeutic action via ion channel reg-
ulation (Gould et al., 2004). Lithium, a simple monovalent cation,
is a ﬁrst-line treatment for BP (Quiroz et al., 2004). Although its
mechanisms of action are not entirely clear (O’Brien and Klein,
2009), there is some evidence that it affects ion channel func-
tioning. A recent investigation of in vitro lithium treatment in
mouse brain tissue determined that, at therapeutic concentrations,
lithium entered the cell through sodium channels and suppressed
theoutwardmembrane current,whichdirectly affectedmembrane
excitability (Butler-Munro et al., 2010). The authors concluded
that ion channels that regulate neuronal excitability may be a
common target among BP treatments. Lithium is also a direct
and potent inhibitor of glycogen synthase kinase 3β (GSK3β;
Klein and Melton, 1996; Quiroz et al., 2004). GSK3β has many
functions, one of which is to phosphorylate the voltage-gated
potassium channel KCNQ2. It has been shown in vitro that
phosphorylation of KCNQ2 decreases the activity of the channel
and subsequently reduces the M-channel current (Borsotto et al.,
2007). It is intriguing to speculate that lithium may have ther-
apeutic effect by blocking this downstream phosphorylation of
KCNQ2. Antiepileptic drugs (AEDs) such as valproate, lamotrig-
ine, and carbamazepine have a long history of successfully treating
BP, and may similarly affect the regulation of neurotransmission
and action potential ﬁring via mediation of ion channel function-
ing. The AEDs that are effective against BP likely have multiple
molecular targets with variable contributions to the drugs’ efﬁcacy
(Perucca, 2005). However, it is notable that they are all known to
diminish the ﬂow and accumulation of sodium ions in the cell
(El-Mallakh and Huff, 2001).
Voltage-gated potassium channels, speciﬁcally the Kv7 chan-
nels, are particularly attractive targets for novel therapeutics for BP.
In addition to their functionally relevant roleswithinneurons, they
offer the ability for selective intervention (Brown and Passmore,
2009). For example, ezogabine (EZG) is a neuronal potassium
channel enhancer that was recently approved by the FDA (Food
and Drug Administration) to treat partial epilepsy (Little, 2009).
It has been shown (Wickenden et al., 2000) that EZG activates the
KCNQ2/KCNQ3 hetero-tetramer ion channel complex, which in
turn promotes the M-current and thereby stabilizes action poten-
tial ﬁring. This action likely accounts for the drug’s anticonvulsant
properties (Borsotto et al., 2007).
Several groups have studied the potential mood-stabilizing
effects of EZG and other Kv7 channel enhancers in a series of
animal studies. One study (Redrobe and Nielsen, 2009) used a
mouse model of mania and determined that EZG (a non-selective
opener) and ICA-27243 (a selective Kv7.2/3 opener), but not BMS-
204352 (a selective Kv7.4–Kv7.5 and Kv7.7/3 heteromer opener)
were able to reduce motility in the hyperactive mice, a paradigm
for antimanic properties in drugs. In another study employing the
D-amphetamine and chlordiazepoxide (AMPH + CDP) mouse
model (Kristensen et al., 2012), EZG reduced cerebral glucose
metabolic activity while increasing phosphor-serine-9 levels of
GSK3β with a brain regional signature that mirrored lithium and
valproate.
Ezogabine has also been evaluated for the acute treatment
for mania in a small (N = 10) open label pilot study of treat-
ment resistant in patients with BP type I (Amann et al., 2006).
Despite the limited sample, the brevity of the study design,
and the severity of illness, improvement in mania scores was
observed in four patients. The treatment was well tolerated with
no depressogenic effects, indicating that further study may be
warranted.
NEURONAL CHANNELOPATHIES
The accumulating evidence from molecular genetic studies pro-
vides a plausible case that BP may be due, at least in part, to
a channelopathy. The term “channelopathy” is a relative new-
comer to the medical lexicon, referring to disorders that result
from defective ion channel functioning (Ashcroft, 2000). Ion
channels are complex, membrane-spanning glycoproteins com-
posed of separate pore-forming and accessory subunits (Ashcroft,
2006). These pores allow the selective, passive transport of charged
ions through the hydrophobic cell membrane, which is otherwise
relatively impermeable to ions. While the actual movement of
the ions themselves is largely inconsequential, it is the resulting
transmembrane current that elicits the electrical excitability that
deﬁnes their physiological contributions (Gargus, 2003). These
currents allow ion channels to orchestrate electrical signals such as
action potentials in neurons (El-Mallakh and Huff, 2001). Action
potentials, which result from transient changes in the membrane’s
permeability to sodium and potassium ions, are electrical events
that encode and transmit information, facilitating neuronal com-
munication via neurotransmitters (Stuart et al., 1997). Sodium
(Na+) channels are responsible for the initial depolarization (or
rising) phase of the action potential, and potassium (K+) chan-
nels are responsible for the repolarizing phase, which returns
the membrane to its resting potential (Barnett and Larkman,
2007).
Ion channel genes are quite prominent, representing 1–2% of
the entire genome (Clare, 2010; Stelzer et al., 2011), and most dis-
play tissue-speciﬁc expression. Ion channels are extraordinarily
diverse, suggesting a high degree of functional speciﬁcity (Rudy,
1999). Their diversity is often ampliﬁed by the various combi-
nations of heteromers between family members that co-assemble
to form functional units of the channels. Additionally, variations
in their different constituent subunits allow for modiﬁcation of
their functioning, through alternative splicing (Gargus, 2003).
Therefore, while ion channels play a role in a broad range of
physiological processes in various tissues, genetic variation in the
genes that code for them often result in tissue-speciﬁc diseases
(Cannon, 2006).
Potassium channels in particular ﬁgure prominently in human
channelopathies (Ryan and Ptacek, 2010). Their structural and
functional diversity, which is greater than any other group of ion
channels (Kress and Mennerick, 2009), underscores the variety of
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physiological function that they modulate (Lawson, 2000). In par-
ticular, variants within the KCNQ gene family (KCNQ1–5, also
referred to as Kv7.1–5) have ﬁgured prominently in human chan-
nelopathies (Gargus, 2006). Of the ten potassium channel genes
that have proven associations with human disease, four are mem-
bers of the KCNQ subfamily (Borsotto et al., 2007). Additionally,
four of the ﬁve KCNQ gene family members have been associ-
ated with different hereditary diseases. The diversity, ubiquity, and
functional signiﬁcance of the KCNQ gene family imply that they
are likely to play a role in the etiology of more diseases than have
already been identiﬁed (Sanguinetti and Spector, 1997; Borsotto
et al., 2007).
As suggested above, two members of the KCNQ gene family
(KCNQ2 andKCNQ3) may be particularly relevant to BP etiology.
KCNQ2 and KCNQ3 are both expressed in the brain and form
hetero and homomeric voltage-gated potassium channels. ANK3
helps to direct the localization of the KCNQ2/KCNQ3 channels
to the axonal initial segment (AIS) of neurons and nodes of Ran-
vier. Indeed, such localization is abolished in ANK3 knock-out
mice (Pan et al., 2006). The crucial role of KCNQ2 and KCNQ3 at
theAIS is to formM-type channels that mediate sub-thresholdM-
currents. TheseM-currents stabilize the neuronal resting potential
and inhibit repetitive ﬁring of action potentials and thereby pre-
vent neuronal hyperactivity (Delmas and Brown, 2005). Thus,
disruption of normal KCNQ2/KCNQ3 activity may be salient to
the etiology of BP. Supporting this hypothesis are animal model
studieswhich have shown that the suppression of theM-current by
dominant-negative mutations in KCNQ2 lead to hyperexcitabil-
ity of neurons, morphological changes of the hippocampus, a
notable decline in cognitive function, and behavioral changes
corresponding to hyperactivity (Peters et al., 2005). Interestingly,
mutations for benign familial convulsions, a rare autosomal dom-
inant inherited form of epilepsy, have been identiﬁed in KCNQ2
(Singh et al., 1998).
BIPOLAR DISORDER AND EPILEPSY
Bipolar disorder has many overlapping features with epilepsy
(Amann and Grunze, 2005; Askland, 2006), which has been
referred to as the“signature channelopathy phenotype in the CNS”
(Gargus, 2006). Epilepsy is a brain disorder involving repeated
and unprovoked seizures, which are periods of disturbed brain
function caused by abnormally excited electrical signals (Vorvick
and Jasmin, 2010). Epilepsy has a number of subtypes that are
proven channelopathies (Heron et al., 2007), and as a result it can
be used as amodel to illustrate other central nervous system (CNS)
conditions that may arise from disruptions of ion channel func-
tioning (Gargus, 2003). In particular, there are many intriguing
parallels between BP and epilepsy that suggest common neuro-
biological basis, speciﬁcally implicating ion channel functioning
(Mazza et al., 2007).
One of the most striking similarities between BP and epilepsy
involves the course of illness for both disorders, which involves a
predominantly normal phenotype punctuated by sporadic inter-
ruption of rhythmic functioning (Gargus, 2006). The episodic
course of both disorders often progresses to become chronic, and
sometimes treatment resistant (Mula et al., 2010). The progres-
sion of these conditions known as “kindling,” whereby repetitive,
sub-threshold stimuli induce episodes until they begin to occur
spontaneously may be a feature of both epilepsy and BP (Amann
and Grunze, 2005). This kindling phenomenon is thought to
leave lasting physiological changes in the brain that predispose
it to be more sensitive to further stressors. Further, AEDs that
are used to treat both epilepsy and BP such as carbamazepine
(Post et al., 1982), valproate (Loscher et al., 1989), and lamot-
rigine (O’Donnell and Miller, 1991) have been shown to exhibit
anti-kindling properties.
Mood disorders are frequently comorbid with epilepsy (Mula
et al., 2008). Earlier ﬁndings suggested that BP was rarely diag-
nosed in epilepsy patients. However, a large population-based
survey in the United States found evidence of BP symptoms in
12.2% of epilepsy patients, and nearly half of these (6%) received
a research-diagnosis of BP from a physician. This rate was higher
than comorbidities of other medical disorders within the epilep-
tic population (Ettinger et al., 2005). This comorbidity is puzzling
given that epilepsypatients are treatedwithAEDs,which arepotent
mood stabilizers (Mula et al., 2008). Additionally, an affective syn-
drome, known as interictal dysphoric disorder (IDD), occurs in
patients with epilepsy anywhere from 0.1 to 4.3% (Robertson,
1992). In a study of 143 outpatients with epilepsy (Mula et al.,
2008), 11.8% received a DSM-IV (Diagnostic and Statistical Man-
ual of Mental Disorders, Fourth Edition) diagnosis of BP, but only
1.4% were considered “pure” BP, unrelated to IDD, seizures, or
AED treatment. Although IDD symptoms are thought to be phys-
iologically distinct from the neurological symptoms of epilepsy
(Gibbs, 1951), it is unclear how the etiology of these bipolar-like
symptoms relates to BP itself. Regardless, it may be reasonable to
speculate that the remarkable similarities in symptoms indicate
some common mechanisms in the pathophysiology, potentially
through ion channelopathies.
Further epidemiological support for etiological overlap
between these disorders comes from a population-based family
study of the comorbidity and familiarity between epilepsy and
psychosis (Clarke et al., 2012). Among patients with epilepsy, the
authors found an increased risk for broadly deﬁned psychosis
(5.5-fold increase in risk), schizophrenia (8.5-fold increase), and
bipolar disorder (6.3-fold increase). Additionally, having a par-
ent with epilepsy conferred a twofold increase risk for psychosis
(compared to individuals without parental history of epilepsy),
and conversely, a parental history of psychosis increased risk for
epilepsy by 2.7-fold.
One ﬁnal intriguing parallel between BP and epilepsy is the
overlap in their treatments. Remarkably, many AEDs, including
carbamazepine, lamotrigine, and valproate are effective in the
treatment of BP. In fact, valproate is considered a ﬁrst-line treat-
ment for acute mania as well as prophylaxis. And carbamazepine
and lamotrigine are other leading alternative mood stabilizers,
should ﬁrst-linemonotherapy with lithium or valproate fail. Lam-
otrigine, in particular, has been shown to be relatively more
effective against bipolar depression (Sachs et al., 2000). Although
the mechanisms of action for these drugs in treating BP may not
necessarily be the same as those in treating epilepsy (Rogawski and
Loscher, 2004), the similarities between the disorders coupledwith
overlapping treatment regimes strongly suggest for at least some
common pathophysiology.
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DISCUSSION
Over the past few decades, countless effort and resources have
been invested into researching the genetic contribution to bipo-
lar disorder. While no genes have been conclusively shown to
cause the disorder, each discovery has revealed a small part
of the fascinatingly complex genetic architecture of BP. Evi-
dence implicating various genes related to the structure and
regulation of ion channels had peppered earlier linkage and
association literature. This class of genes has garnered renewed
support in the GWAS era, as both single SNP and pathways
based analyses continue to implicate ion channel functioning.
The course of illness of BP, speciﬁcally its episodic nature, ﬁts
well with the channelopathy paradigm. Thus, these ion chan-
nel genes, which profoundly impact the neuronal activity, are
an interesting group as there is both statistical evidence as well
as biological plausibility implicating their involvement. Much
of the focus has been on the potential role of calcium ion
channels in BP. Here, we review evidence that potassium ion
channels may also contribute to the etiology and deserve further
investigation.
The identiﬁcation of genes that contribute to BP susceptibility
is important for a number of reasons. Elucidating the genetic
underpinnings of BP may reveal new treatment targets, facil-
itating rational drug design that could produce more effective
therapeutics with fewer side effects (U.S. Department of Energy
Genome Program, 2009). It could also facilitate the development
of diagnostic testing via genetic screening. This may have clinical
implications, particularly in the case of disorders with genetic het-
erogeneity, whereby the course of treatment may depend on the
precise etiology of the disorder (Ashcroft, 2000).
REFERENCES
Amann, B., and Grunze, H. (2005).
Neurochemical underpinnings in
bipolar disorder and epilepsy. Epilep-
sia 46(Suppl. 4), 26–30. doi:
10.1111/j.1528-1167.2005.463006.x
Amann, B., Sterr, A., Vieta, E.,
Stampfer, R., Walden, J., and
Grunze, H. (2006). An exploratory
open trial on safety and efﬁcacy
of the anticonvulsant retigabine in
acute manic patients. J. Clin. Psy-
chopharmacol. 26, 534–536. doi:
10.1097/01.jcp.0000236661.95200.3e
Ashcroft, F.M. (2000). Ion Channels and
Disease. San Diego, CA: Academic
Press, 465 p.
Ashcroft, F. M. (2006). From molecule
to malady. Nature 440, 440–447. doi:
10.1038/nature04707
Askland, K. (2006). Toward a biaxial
model of “bipolar” affective disor-
ders: further exploration of genetic,
molecular and cellular substrates.
J. Affect. Disord. 94, 35–66. doi:
10.1016/j.jad.2006.01.033
Askland, K., and Parsons, M. (2006).
Toward a biaxial model of “bipolar”
affective disorders: spectrum pheno-
types as the products of neuroelec-
trical and neurochemical alterations.
J. Affect. Disord. 94, 15–33. doi:
10.1016/j.jad.2006.02.024
Askland, K., Read, C., and Moore, J.
(2009). Pathways-based analyses of
whole-genome association study data
in bipolar disorder reveal genesmedi-
ating ion channel activity and synap-
tic neurotransmission. Hum. Genet.
125, 63–79. doi: 10.1007/s00439-008-
0600-y
Avramopoulos, D.,Willour,V. L., Zandi,
P. P., Huo, Y., MacKinnon, D. F.,
Potash, J. B., et al. (2004). Linkage of
bipolar affective disorder on chromo-
some8q24: follow-up andparametric
analysis. Mol. Psychiatry 9, 191–196.
doi: 10.1038/sj.mp.4001388
Barnett, J. H., and Smoller, J. W.
(2009). The genetics of bipolar disor-
der. Neuroscience 121, 373–382. doi:
10.1016/j.neuroscience.2009.03.080
Barnett, M. W., and Larkman, P. M.
(2007). The action potential. Pract.
Neurol. 7, 192–197.
Baum, A. E., Akula, N., Cabanero, M.,
Cardona, I., Corona,W., Klemens, B.,
et al. (2008). A genome-wide associ-
ation study implicates diacylglycerol
kinase eta (DGKH) and several other
genes in the etiology of bipolar disor-
der. Mol. Psychiatry 13, 197–207. doi:
10.1038/sj.mp.4002012
Borsotto, M., Cavarec, L., Bouillot, M.,
Romey, G., Macciardi, F., Delaye, A.,
et al. (2007). PP2A-bgamma subunit
and KCNQ2 K+ channels in bipo-
lar disorder. Pharmacogenomics J. 7,
123–132. doi: 10.1038/sj.tpj.6500400
Brown, D. A., and Passmore, G. M.
(2009). Neural KCNQ (Kv7) chan-
nels. Br. J. Pharmacol. 156, 1185–
1195. doi: 10.1111/j.1476-5381.
2009.00111.x
Butler-Munro, C., Coddington, E.
J., Shirley, C. H., and Heyward,
P. M. (2010). Lithium modulates
cortical excitability in vitro. Brain
Res. 1352, 50–60. doi: 10.1016/
j.brainres.2010.07.021
Cannon, S. C. (2006). Pathomecha-
nisms in channelopathies of skeletal
muscle and brain. Annu. Rev. Neu-
rosci. 29, 387–415. doi: 10.1146/
annurev.neuro.29.051605.112815
Casamassima, F., Hay, A. C., Benedetti,
A., Lattanzi, L., Cassano, G. B., and
Perlis, R. H. (2010). L-type calcium
channels and psychiatric disorders: a
brief review. Am. J. Med. Genet. B
Neuropsychiatr. Genet. 153B, 1373–
1390. doi: 10.1002/ajmg.b.31122
Chandy, K. G., Fantino, E., Wittekindt,
O., Kalman, K., Tong, L. L., Ho, T.
H., et al. (1998). Isolation of a novel
potassium channel gene hSKCa3
containing a polymorphic CAG
repeat: a candidate for schizo-
phrenia and bipolar disorder? Mol.
Psychiatry 3, 32–37. doi: 10.1038/
sj.mp.4000353
Cichon, S., Schumacher, J., Muller,
D. J., Hurter, M., Windemuth, C.,
Strauch, K., et al. (2001). A genome
screen for genes predisposing to bipo-
lar affective disorder detects a new
susceptibility locus on 8q. Hum.
Mol. Genet. 10, 2933–2944. doi:
10.1093/hmg/10.25.2933
Clare, J. J. (2010). Targeting ion chan-
nels for drug discovery. Discov. Med.
9, 253–260.
Clarke,M. C., Tanskanen,A., Huttunen,
M. O., Clancy, M., Cotter, D. R.,
and Cannon, M. (2012). Evidence
for shared susceptibility to epilepsy
and psychosis: a population-based
family study. Biol. Psychiatry 71, 836–
839. doi: 10.1016/j.biopsych.2012.
01.011
Craddock, N., and Jones, I. (1999).
Genetics of bipolar disorder. J.
Med. Genet. 36, 585–594. doi:
10.1016/S0140-6736(13)60855-7
Craddock, N., and Sklar, P. (2009).
Genetics of bipolar disorder: success-
ful start to a long journey. Trends
Genet. 25, 99–105. doi: 10.1016/
j.tig.2008.12.002
Cross-Disorder Group of the Psychi-
atric Genomics Consortium, Smoller,
J. W., Craddock, N., Kendler, K.,
Lee, P. H., Neale, B. M., et al.
(2013). Identiﬁcation of risk loci
with shared effects on ﬁve major
psychiatric disorders: a genome-
wide analysis. Lancet 381, 1371–
1379. doi: 10.1016/S0140-6736(12)
62129-1
Delmas, P., and Brown, D. A.
(2005). Pathways modulating neural
KCNQ/M (Kv7) potassium channels.
Nat. Rev. Neurosci. 6, 850–862. doi:
10.1038/nrn1785
Duncan, C. E., Chetcuti, A. F., and
Schoﬁeld, P. R. (2008). Coreg-
ulation of genes in the mouse
brain following treatment with cloza-
pine, haloperidol, or olanzap-
ine implicates altered potassium
channel subunit expression in the
mechanism of antipsychotic drug
action. Psychiatr. Genet. 18, 226–
239. doi: 10.1097/YPG.0b013e328
3053019
El-Mallakh, R. S., and Huff, M. O.
(2001). Mood stabilizers and ion
regulation. Harv. Rev. Psychiatry
9, 23–32. doi: 10.1080/106732201
27873
el-Mallakh, R. S., and Wyatt, R. J.
(1995). TheNa, K-ATPase hypothesis
for bipolar illness. Biol. Psychia-
try 37, 235–244. doi: 10.1016/0006-
3223(94)00201-D
Ettinger, A. B., Reed, M. L., Gold-
berg, J. F., and Hirschfeld, R.
M. (2005). Prevalence of bipo-
lar symptoms in epilepsy vs other
chronic health disorders. Neurol-
ogy 65, 535–540. doi: 10.1212/
01.wnl.0000172917.70752.05
Fangerau, H., Ohlraun, S., Granath, R.
O., Nothen, M. M., Rietschel, M.,
and Schulze, T. G. (2004). Computer-
assisted phenotype characterization
for genetic research in psychiatry.
Hum. Hered. 58, 122–130. doi:
10.1159/000083538
Ferreira, M. A., O’Donovan, M. C.,
Meng, Y. A., Jones, I. R., Ruderfer,
D. M., Jones, L., et al. (2008). Col-
laborative genome-wide association
analysis supports a role for ANK3
and CACNA1C in bipolar disorder.
Nat. Genet. 40, 1056–1058. doi:
10.1038/ng.209
Friddle, C., Koskela, R., Ranade, K.,
Hebert, J., Cargill, M., Clark, C. D.,
et al. (2000). Full-genome scan for
linkage in 50 families segregating the
bipolar affective disease phenotype.
Frontiers in Genetics | Behavioral and Psychiatric Genetics June 2013 | Volume 4 | Article 105 | 6
“fgene-04-00105” — 2013/6/8 — 18:54 — page 7 — #7
Judy and Zandi Potassium channels in bipolar disorder
Am. J. Hum. Genet. 66, 205–215. doi:
10.1086/302697
Gargus, J. J. (2003). Unraveling mono-
genic channelopathies and their
implications for complex polygenic
disease. Am. J. Hum. Genet. 72,
785–803. doi: 10.1086/374317
Gargus, J. J. (2006). Ion chan-
nel functional candidate genes in
multigenic neuropsychiatric disease.
Biol. Psychiatry 60, 177–185. doi:
10.1016/j.biopsych.2005.12.008
Gibbs, F. A. (1951). Ictal and non-
ictal psychiatric disorders in temporal
lobe epilepsy. J. Nerv. Ment. Dis. 113,
522–528.
Glatt, S. J., Faraone, S. V., and Tsuang,
M. T. (2003). CAG-repeat length in
exon 1 of KCNN3 does not inﬂuence
risk for schizophrenia or bipolar dis-
order: a meta-analysis of association
studies. Am. J. Med. Genet. B Neu-
ropsychiatr. Genet. 121B, 14–20. doi:
10.1002/ajmg.b.20048
Gould, T. D., Quiroz, J. A., Singh,
J., Zarate, C. A., and Manji, H.
K. (2004). Emerging experimen-
tal therapeutics for bipolar disorder:
insights from the molecular and cel-
lular actions of current mood stabi-
lizers. Mol. Psychiatry 9, 734–755.
doi: 10.1038/sj.mp.4001518
Grube, S., Gerchen, M. F., Adam-
cio, B., Pardo, L. A., Martin, S.,
Malzahn, D., et al. (2011). A CAG
repeat polymorphismof KCNN3pre-
dicts SK3 channel function and cog-
nitive performance in schizophrenia.
EMBO Mol. Med. 3, 309–319. doi:
10.1002/emmm.201100135
Hawi, Z., Mynett-Johnson, L., Mur-
phy, V., Straub, R. E., Kendler, K.
S., Walsh, D., et al. (1999). No evi-
dence to support the association of
the potassium channel gene hSKCa3
CAG repeat with schizophrenia or
bipolar disorder in the Irish popula-
tion. Mol. Psychiatry 4, 488–491. doi:
10.1038/sj.mp.4000560
Heron, S. E., Scheffer, I. E., Berkovic,
S. F., Dibbens, L. M., and Mul-
ley, J. C. (2007). Channelopathies
in idiopathic epilepsy. Neu-
rotherapeutics 4, 295–304. doi:
10.1016/j.nurt.2007.01.009
Hjaeresen, M. L., Hageman, I.,
Wortwein, G., Plenge, P., and Jor-
gensen, M. B. (2008). Chronic
electroconvulsive stimulation but
not chronic restraint stress modu-
lates mRNA expression of voltage-
dependent potassium channels Kv7.2
and Kv11.1 in the rat piriform cor-
tex. Brain Res. 1217, 179–184. doi:
10.1016/j.brainres.2007.09.071
Klein, P. S., and Melton, D. A. (1996). A
molecular mechanism for the effect
of lithium on development. Proc.
Natl. Acad. Sci. U.S.A. 93, 8455–8459.
doi: 10.1073/pnas.93.16.8455
Kress, G. J., and Mennerick, S.
(2009). Action potential initia-
tion and propagation: upstream
inﬂuences on neurotransmission.
Neuroscience 158, 211–222. doi:
10.1016/j.neuroscience.2008.03.021
Kristensen, L. V., Sandager-Nielsen, K.,
and Hansen, H. H. (2012). K(v) 7
(KCNQ) channel openers normal-
ize central 2-deoxyglucose uptake
in a mouse model of mania and
increase prefrontal cortical and hip-
pocampal serine-9 phosphorylation
levels of GSK3beta. J. Neurochem.
164, 331–343. doi: 10.1111/j.1471-
4159.2012.07704.x
Lawson, K. (2000). Is there a role for
potassium channel openers in neu-
ronal ion channel disorders? Expert
Opin. Investig. Drugs 9, 2269–2280.
doi: 10.1517/13543784.9.10.2269
Lee, M. T., Chen, C. H., Lee, C. S.,
Chen, C. C., Chong, M. Y., Ouyang,
W. C., et al. (2010). Genome-wide
association study of bipolar I disor-
der in the Han Chinese population.
Mol. Psychiatry 16, 548–556. doi:
10.1038/mp.2010.43
Le-Niculescu, H., Patel, S. D., Bhat, M.,
Kuczenski, R., Faraone, S. V., Tsuang,
M. T., et al. (2009). Convergent
functional genomics of genome-wide
association data for bipolar disor-
der: comprehensive identiﬁcation of
candidate genes, pathways andmech-
anisms. Am. J. Med. Genet. B Neu-
ropsychiatr. Genet. 150B, 155–181.
doi: 10.1002/ajmg.b.30887
Little, L.W. (2009). Retigabine NDA Ac-
cepted for Filing. Available at: http://
www.drugs.com/nda/retigabine_
091230.html
Loscher, W., Fisher, J. E., Nau, H.,
and Honack, D. (1989). Valproic acid
in amygdala-kindled rats: alterations
in anticonvulsant efﬁcacy, adverse
effects and drug and metabolite lev-
els in various brain regions during
chronic treatment. J. Pharmacol. Exp.
Ther. 250, 1067–1078.
Mayo Clinic. (2010). Electroconvul-
sive Therapy (ECT). Rochester: Mayo
Clinic.
Mazza, M., Di Nicola, M., Della
Marca, G., Janiri, L., Bria, P.,
and Mazza, S. (2007). Bipo-
lar disorder and epilepsy: a bidi-
rectional relation? neurobiological
underpinnings, current hypothe-
ses, and future research directions.
Neuroscientist 13, 392–404. doi:
10.1177/10738584070130041101
McInnis, M. G., Breschel, T. S., Mar-
golis, R. L., Chellis, J., MacKinnon,
D. F., McMahon, F. J., et al. (1999).
Family-based association analysis of
the hSKCa3 potassium channel gene
in bipolar disorder. Mol. Psychiatry 4,
217–219. doi: 10.1038/sj.mp.4000492
McInnis, M. G., Lan, T. H., Willour,
V. L., McMahon, F. J., Simpson,
S. G., Addington, A. M., et al.
(2003). Genome-wide scan of bipo-
lar disorder in 65 pedigrees: sup-
portive evidence for linkage at 8q24,
18q22, 4q32, 2p12, and 13q12.
Mol. Psychiatry 8, 288–298. doi:
10.1038/sj.mp.4001277
McQueen, M. B., Devlin, B., Faraone,
S. V., Nimgaonkar, V. L., Sklar, P.,
Smoller, J. W., et al. (2005). Com-
bined analysis from eleven linkage
studies of bipolar disorder provides
strong evidence of susceptibility loci
on chromosomes 6q and 8q. Am.
J. Hum. Genet. 77, 582–595. doi:
10.1086/491603
Mula, M., Marotta, A. E., and Monaco,
F. (2010). Epilepsy and bipolar dis-
orders. Expert Rev. Neurother. 10,
13–23. doi: 10.1586/ern.09.139
Mula, M., Schmitz, B., Jauch, R.,
Cavanna, A., Cantello, R., Monaco,
F., et al. (2008). On the preva-
lence of bipolar disorder in epilepsy.
Epilepsy Behav. 13, 658–661. doi:
10.1016/j.yebeh.2008.08.002
Newton, J. R. (2007). Linked gene
ontology categories are novel and dif-
fer from associated gene ontology
categories for the bipolar disorders.
Psychiatr. Genet. 17, 29–34. doi:
10.1097/YPG.0b013e328010f28c
O’Brien, W. T., and Klein, P. S.
(2009). Validating GSK3 as an in vivo
target of lithium action. Biochem.
Soc. Trans. 37, 1133–1138. doi:
10.1042/BST0371133
O’Donnell, R. A., and Miller, A.
A. (1991). The effect of lamotrig-
ine upon development of cortical
kindled seizures in the rat. Neu-
ropharmacology 30, 253–258. doi:
10.1016/0028-3908(91)90152-2
Overington, J. P., Al-Lazikani, B., and
Hopkins, A. L. (2006). How many
drug targets are there? Nat. Rev.
Drug. Discov. 5, 993–996. doi:
10.1038/nrd2199
Pan, Z., Kao, T., Horvath, Z.,
Lemos, J., Sul, J. Y., Cranstoun,
S. D., et al. (2006). A common
ankyrin-G-based mechanism retains
KCNQ and NaV channels at elec-
trically active domains of the axon.
J. Neurosci. 26, 2599–2613. doi:
10.1523/JNEUROSCI.4314-05.2006
Pei, Q., Burnet, P. W., Grahame-
Smith, D. G., and Zetterstrom, T.
S. (1997). Differential effects of
acute and chronic electroconvulsive
shock on the abundance of mes-
senger RNAs for voltage-dependent
potassium channel subunits in the rat
brain. Neuroscience 78, 343–350. doi:
10.1016/S0306-4522(96)00574-X
Perucca, E. (2005). An introduc-
tion to antiepileptic drugs. Epilep-
sia 46(Suppl. 4), 31–37. doi:
10.1111/j.1528-1167.2005.463007.x
Peters, H. C., Hu, H., Pongs, O.,
Storm, J. F., and Isbrandt, D. (2005).
Conditional transgenic suppression
of M channels in mouse brain reveals
functions in neuronal excitability,
resonance and behavior. Nat. Neu-
rosci. 8, 51–60. doi: 10.1038/nn1375
Post, R. M., Uhde, T. W., Putnam,
F. W., Ballenger, J. C., and Berret-
tini, W. H. (1982). Kindling and
carbamazepine in affective illness. J.
Nerv. Ment. Dis. 170, 717–731. doi:
10.1097/00005053-198212000-00002
Psychiatric GWAS Consortium Bipo-
lar Disorder Working Group. (2011).
Large-scale genome-wide association
analysis of bipolar disorder identi-
ﬁes a new susceptibility locus near
ODZ4. Nat. Genet. 43, 977–983. doi:
10.1038/ng.943
Psychiatric GWAS Consortium Coor-
dinating Committee, Cichon, S.,
Craddock, N., Daly, M., Faraone,
S. V., Gejman, P. V., Kelsoe, J.,
et al. (2009). Genomewide associa-
tion studies: history, rationale, and
prospects for psychiatric disorders.
Am. J. Psychiatry 166, 540–556. doi:
10.1176/appi.ajp.2008.08091354
Quiroz, J. A., Gould, T. D., and Manji,
H. K. (2004). Molecular effects of
lithium. Mol. Interv. 4, 259–272. doi:
10.1124/mi.4.5.6
Redrobe, J. P., and Nielsen, A. N.
(2009). Effects of neuronalKv7potas-
sium channel activators on hyperac-
tivity in a rodent model of mania.
Behav. Brain Res. 198, 481–485. doi:
10.1016/j.bbr.2008.12.027
Robertson, M. M. (1992). Affect
and mood in epilepsy: an overview
with a focus on depression. Acta
Neurol. Scand. Suppl. 140, 127–132.
doi: 10.1111/j.1600-0404.1992.tb0
4481.x
Rogawski, M. A., and Loscher,
W. (2004). The neurobiology of
antiepileptic drugs for the treatment
of nonepileptic conditions.Nat. Med.
10, 685–692. doi: 10.1038/nm1074
Rohrmeier, T., Putzhammer, A.,
Schoeler, A., Sartor, H., Dallinger,
P., Nothen, M. M., et al. (1999).
hSKCa3: no association of the poly-
morphic CAG repeat with bipolar
affective disorder and schizophrenia.
Psychiatr. Genet. 9, 169–175. doi:
10.1097/00041444-199912000-00001
Rudy, B. (1999). Molecular diversity
of ion channels and cell function.
Ann. N. Y. Acad. Sci. 868, 1–12. doi:
10.1111/j.1749-6632.1999.tb11269.x
www.frontiersin.org June 2013 | Volume 4 | Article 105 | 7
“fgene-04-00105” — 2013/6/8 — 18:54 — page 8 — #8
Judy and Zandi Potassium channels in bipolar disorder
Ryan, D. P., and Ptacek, L. J.
(2010). Episodic neurological chan-
nelopathies.Neuron 68, 282–292. doi:
10.1016/j.neuron.2010.10.008
Sachs, G. S., Printz, D. J., Kahn, D.
A., Carpenter, D., and Docherty, J. P.
(2000). The expert consensus guide-
line series: medication treatment of
bipolar disorder 2000. Postgrad. Med.
Spec No. 1-104.
Sackeim, H. A. (1999). The anticonvul-
sant hypothesis of themechanisms of
action of ECT: current status. J. ECT
15, 5–26. doi: 10.1097/00124509-
199903000-00003
Sanguinetti, M. C., and Spector,
P. S. (1997). Potassium channelo-
pathies. Neuropharmacology 36, 755–
762. doi: 10.1016/S0028-3908(97)
00029-4
Schulze, T. G., Detera-Wadleigh, S. D.,
Akula, N., Gupta, A., Kassem, L.,
Steele, J., et al. (2009). Two variants
in ankyrin 3 (ANK3) are independent
genetic risk factors for bipolar disor-
der. Mol. Psychiatry 14, 487–491. doi:
10.1038/mp.2008.134
Scott, L. J., Muglia, P., Kong, X. Q.,
Guan, W., Flickinger, M., Upmanyu,
R., et al. (2009). Genome-wide asso-
ciation and meta-analysis of bipolar
disorder in individuals of Euro-
pean ancestry. Proc. Natl. Acad.
Sci. U.S.A. 106, 7501–7506. doi:
10.1073/pnas.0813386106
Singh, N. A., Charlier, C., Stauffer, D.,
DuPont, B. R., Leach, R. J., Melis,
R., et al. (1998). A novel potassium
channel gene, KCNQ2, is mutated
in an inherited epilepsy of new-
borns. Nat. Genet. 18, 25–29. doi:
10.1038/ng0198-25
Sklar, P., Smoller, J. W., Fan, J., Fer-
reira, M. A., Perlis, R. H., Cham-
bert, K., et al. (2008). Whole-genome
association study of bipolar disor-
der. Mol. Psychiatry 13, 558–569. doi:
10.1038/sj.mp.4002151
Smith, E. N., Bloss, C. S., Badner, J. A.,
Barrett, T., Belmonte, P. L., Berret-
tini, W., et al. (2009). Genome-wide
association study of bipolar disorder
in European American and African
American individuals. Mol. Psychi-
atry 14, 755–763. doi: 10.1038/mp.
2009.43
Smolin, B., Karry, R., Gal-Ben-Ari, S.,
and Ben-Shachar, D. (2012). Dif-
ferential expression of genes encod-
ing neuronal ion-channel subunits
in major depression, bipolar dis-
order and schizophrenia: implica-
tions for pathophysiology. Int. J.
Neuropsychopharmacol. 15, 869–
882. doi: 10.1017/S146114571100
1428
Stelzer, G., Dalah, I., Iny Stein,
T., Satanower, Y., Rosen, N.,
Nativ, N., et al. (2011). In-silico
human genomics with GeneCards.
Hum. Genomics 6, 709–717. doi:
10.1186/1479-7364-5-6-709
Stuart, G., Spruston, N., Sakmann,
B., and Hausser, M. (1997). Action
potential initiation andbackpropaga-
tion in neurons of the mammalian
CNS. Trends Neurosci. 20, 125–
131. doi: 10.1016/S0166-2236(96)
10075-8
Szklarczyk, D., Franceschini, A.,
Kuhn, M., Simonovic, M., Roth,
A., Minguez, P., et al. (2011).
The STRING database in 2011:
functional interaction networks
of proteins, globally integrated
and scored. Nucleic Acids Res. 39,
D561–D568. doi: 10.1093/nar/
gkq973
U.S. Department of Energy Genome
Program. (2009). Potential Beneﬁts
of the Human Genome Project. Avail-
able at: http://www.ornl.gov/sci/
techresources/Human_Genome/
project/beneﬁts.shtml
Versiani, M., Cheniaux, E., and
Landeira-Fernandez, J. (2010). Efﬁ-
cacy and safety of electrocon-
vulsive therapy in the treatment
of bipolar disorder: a systematic
review. J. ECT 27, 153–164. doi:
10.1097/YCT.0b013e3181e6332e
Vorvick, L., and Jasmin, L. (2010).
Epilepsy. Available at: http://www.
ncbi.nlm.nih.gov/pubmedhealth/
PMH0001714/
Weissman, M. M., Bland, R. C.,
Canino, G. J., Faravelli, C., Green-
wald, S., Hwu, H. G., et al.
(1996). Cross-national epidemiol-
ogy of major depression and bipo-
lar disorder. JAMA 276, 293–
299. doi: 10.1001/jama.1996.0354004
0037030
Wellcome Trust Case Control Consor-
tium. (2007). Genome-wide associ-
ation study of 14,000 cases of seven
common diseases and 3,000 shared
controls. Nature 447, 661–678. doi:
10.1038/nature05911
Wickenden, A. D., Yu, W., Zou, A.,
Jegla, T., and Wagoner, P. K. (2000).
Retigabine, a novel anti-convulsant,
enhances activation of KCNQ2/Q3
potassium channels. Mol. Pharmacol.
58, 591–600.
Wittekindt, O., Jauch, A., Burgert,
E., Scharer, L., Holtgreve-Grez, H.,
Yvert, G., et al. (1998). The human
small conductance calcium-regulated
potassium channel gene (hSKCa3)
contains twoCAGrepeats in exon1, is
on chromosome 1q21.3, and shows a
possible association with schizophre-
nia. Neurogenetics 1, 259–265. doi:
10.1007/s100480050038
Zandi, P. P., Avramopoulos, D.,Willour,
V. L., Huo, Y., Miao, K., Mackinnon,
D. F., et al. (2007). SNP ﬁne map-
ping of chromosome 8q24 in bipolar
disorder. Am. J. Med. Genet. B Neu-
ropsychiatr. Genet. 144B, 625–630.
doi: 10.1002/ajmg.b.30486
Zhang, P., Xiang, N., Chen, Y., Sliwer-
ska, E., McInnis, M. G., Burmeister,
M., et al. (2010). Family-based asso-
ciation analysis to ﬁnemap bipolar
linkage peak on chromosome 8q24
using 2,500 genotyped SNPs and
15,000 imputed SNPs. BipolarDisord.
12, 786–792. doi: 10.1111/j.1399-
5618.2010.00883.x
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 01 March 2013; paper pend-
ing published: 23 April 2013; accepted:
22 May 2013; published online: 11 June
2013.
Citation: Judy JT and Zandi PP (2013)
A review of potassium channels in bipo-
lar disorder. Front. Genet. 4:105. doi:
10.3389/fgene.2013.00105
This article was submitted to Frontiers
in Behavioral and Psychiatric Genetics,
a specialty of Frontiers in Genetics.
Copyright © 2013 Judy and Zandi. This
is an open-access article distributed under
the terms of the Creative Commons
Attribution License, which permits use,
distribution and reproduction in other
forums, provided the original authors and
source are credited and subject to any
copyright notices concerning any third-
party graphics etc.
Frontiers in Genetics | Behavioral and Psychiatric Genetics June 2013 | Volume 4 | Article 105 | 8
